Business Information
The group's principal activity is to develop pharmaceutical products for the reproductive system, including sexual dysfunction, vaccine adjuvants, fertility and female health as well as urological applications, specifically prostate cancer. The major products are vasomax(R), vasofem(tm), bimexes(tm) and erxin(tm). Vasomax(R) is a disintegrating oral formulation of phentolamine for the treatment of med. Vasofem(tm) is being developed by the group to treat female sexual dysfunction (fsd). Bimexes(tm) is a second generation, multi-component oral therapy for med that acts on multiple physiological pathways. The sexual dysfunction products incorporate phentolamine, an alpha-adrenergic blocker, as the active agent. Erxin(tm) is a multi-component injection therapy, which includes phentolamine.
|
|
Name |
Title
|
Email
|
| Daniel Cain | Chmn. | N/A | | Louis Ploth | Dir., VP - Business Development, CFO, Sec. | N/A | | Ronald Wiehle | VP - Research, Development | N/A | | David Poorvin | Dir. | N/A | | Jean Fourcroy | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 596 | (14,195) | | 2005 | 634 | (7,391) | | 2004 | 257 | (3,697)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
